Synonym
PNU-96391; OSU-6162; PNU96391; OSU6162; PNU 96391; OSU 6162; (S)-(-)-OSU-6162
IUPAC/Chemical Name
3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine
InChi Key
GZVBVBMMNFIXGE-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H23NO2S/c1-3-9-16-10-5-7-14(12-16)13-6-4-8-15(11-13)19(2,17)18/h4,6,8,11,14H,3,5,7,9-10,12H2,1-2H3
SMILES Code
CCCN1CC(C2=CC=CC(S(=O)(C)=O)=C2)CCC1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
281.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Yamazaki S, Toth LN, Black ML, Duncan JN. Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans. Drug Metab Dispos. 2004 Apr;32(4):398-404. PubMed PMID: 15039292.
2: Rodríguez CA, Azie NE, Adams G, Donaldson K, Francom SF, Staton BA, Bombardt PA. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers. J Clin Pharmacol. 2004 Mar;44(3):276-83. PubMed PMID: 14973308.
3: Yamazaki S, Toth LN, Kimoto E, Bower J, Skaptason J, Romero D, Heath TG. Application of stable isotope methodology in the evaluation of the pharmacokinetics of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride in rats. Drug Metab Dispos. 2009 May;37(5):937-45. doi: 10.1124/dmd.108.025478. PubMed PMID: 19237512.
4: Wienkers LC, Wynalda MA. Multiple cytochrome P450 enzymes responsible for the oxidative metabolism of the substituted (S)-3-phenylpiperidine, (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, in human liver microsomes. Drug Metab Dispos. 2002 Dec;30(12):1372-7. PubMed PMID: 12433806.
5: Hutzler JM, Powers FJ, Wynalda MA, Wienkers LC. Effect of carbonate anion on cytochrome P450 2D6-mediated metabolism in vitro: the potential role of multiple oxygenating species. Arch Biochem Biophys. 2003 Sep 15;417(2):165-75. PubMed PMID: 12941298.
6: Hadj Tahar A, Ekesbo A, Grégoire L, Bangassoro E, Svensson KA, Tedroff J, Bédard PJ. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys. Eur J Pharmacol. 2001 Feb 2;412(3):247-54. PubMed PMID: 11166288.
7: Neu H, Hartvig P, Torstenson R, Fasth KJ, Sonesson C, Waters N, Carlsson A, Tedroff J, Långström B. Synthesis of [11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography. Nucl Med Biol. 1997 Aug;24(6):507-11. PubMed PMID: 9316077.
